RS Finn

A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).

J. O’Shaughnessy, Lee S. Schwartzberg, Michael Danso et al. · Journal of Clinical Oncology · 2011 · 244 citations

Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)

RS Finn, JP Crown, István Láng et al. · Cancer Research · 2012 · 128 citations

Breast Oncology, Pharmacotherapy, Tumor Biology +18

Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.

RS Finn, Carmelo Bengala, Nuhad Ibrahim et al. · Cancer Research · 2009 · 70 citations

Breast Oncology, Cancer Management, Pathology +17

An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC)

Jean‐Luc Raoul, RS Finn, Yoon‐Koo Kang et al. · Journal of Clinical Oncology · 2009 · 68 citations

Collagen Iv, Serum Collagen Iv, Pathology +20

A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results

Josep M. Llovet, Karen Shepard, RS Finn et al. · Annals of Oncology · 2019 · 67 citations · Full text

Hepatology, Medicine, Pharmacology +9